On July 23-24, 2026, an FDA advisory committee voted on seven peptides. Headlines called it approval. It wasn't. Here is what happened, what it changes, and what it does not change for patients.
The FDA did not approve any peptide in July 2026. The Pharmacy Compounding Advisory Committee recommended that six of seven reviewed substances - BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax - be added to the Section 503A Bulk Drug Substances List, which governs ingredients a licensed pharmacy may use when preparing a medication for an individual patient with a prescription. Emideltide (DSIP) was not recommended. The votes are advisory and nonbinding; the FDA has not made a final decision, and nothing about patient access changed on the day of the vote.
An advisory committee gives the FDA expert advice. The agency is not required to follow it. Before this meeting, FDA staff recommended against adding all seven substances; the committee went the other way on six.
Approval of a drug is a different and much higher bar: controlled clinical trials, a defined dose, a standardized manufacturing process, a reviewed safety profile, and approved prescribing information. Adding a bulk substance to the 503A list is a decision about what a pharmacy may use as an ingredient - not a finding that a finished medication works.
The regulatory direction changed. Patient access did not. If the FDA ultimately adds a peptide to the list, a licensed U.S. pharmacy could have a clearer legal path to prepare it for an individual patient with a prescription - with physician screening, pharmacy labeling and dosing instructions, accountable sourcing, and follow-up on side effects.
Compounded medications are prepared by licensed U.S. 503A/503B pharmacies. Compounded preparations are not FDA-approved.
A product labeled "research use only" or "not for human consumption" is outside the prescription-drug supply chain. Do not assume its identity, strength, sterility, or suitability for human use. Competitive athletes should also note that BPC-157 and TB-500 are prohibited under World Anti-Doping Agency rules.
GOAL.MD serves patients in all 50 US states. Which medication your physician can prescribe still depends on your state's rules, your medical evaluation, and pharmacy eligibility.
Questions? Call 314-907-3103 or toll-free 800-674-2855, Monday–Friday, 9am–5pm Central, or email customer@jellyfish.md.
The FDA panel recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A list — and rejected DSIP. A recommendation is not approval. Here's what changed.